Technical Guidance Annex B
Information on Quality Premium

Contents

Contents ................................................................. 1

2018/19 Scheme .......................................................... 2
1 Background ................................................................... 2
2 Value ........................................................................ 2
3 Composition of the Quality Premium Scheme ......................... 2
   3.1 Indicators ............................................................ 3
   3.2 Gateways ............................................................ 3
      3.2.1 Quality Gateway ........................................... 4
      3.2.2 Financial Gateway ........................................ 4
      3.2.3 NHS Constitution Gateway ............................. 5
4 Calculation and use of Quality Premium payments ................. 5

Appendix 1: Quality Premium measures (2018/19 Scheme) .......... 7

Appendix 2: 2017/18 Scheme .............................................. 34

Appendix 3: Quality Premium measures (2017/18 Scheme) .......... 39

This Annex was republished in April 2018 under Gateway Reference 07905 with the following updates:

<table>
<thead>
<tr>
<th>Page</th>
<th>Update</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Updated structure of the QP scheme in line with the published Planning Guidance, to include Demand Management Indicators.</td>
</tr>
<tr>
<td>4</td>
<td>Updated Financial Gateway.</td>
</tr>
<tr>
<td>5</td>
<td>Streamlined NHS Constitutional Gateway.</td>
</tr>
<tr>
<td>15 - 22</td>
<td>Updated Mental Health indicator to provide better explanation in line with user feedback.</td>
</tr>
<tr>
<td>23 - 33</td>
<td>Updated GNBSI indicator to provide better explanation in line with user feedback and updated thresholds in line with previous published guidance.</td>
</tr>
</tbody>
</table>
2018/19 Scheme

1 Background

The Quality Premium (QP) scheme is about rewarding Clinical Commissioning Groups (CCGs) for improvements in the quality of the services they commission. The scheme also incentivises CCGs to improve patient health outcomes and reduce inequalities in health outcomes and improve access to services.

As in previous years, it is important that we retain a focus on the fundamentals of everyday commissioning. The QP scheme has been updated to align with the requirements in the 18/19 Planning Guidance on the moderation of emergency care demand. The QP scheme will continue to improve progress on key quality priorities such as cancer, mental health, RightCare and bloodstream infections.

2 Value

Under the National Health Service Act 2006 (as amended by the Health and Social Care Act 2012), NHS England has the power to make payments to CCGs to reflect the quality of services that they commission, the associated health outcomes and reductions in inequalities.

In keeping with previous years, the maximum QP payment for a CCG is expressed as £5 per head of population, calculated using the same methodology as for CCG running costs, and made as a programme allocation (this is in addition to a CCG’s main financial allocation and its running costs allowance).

3 Composition of the Quality Premium Scheme

The QP paid to CCGs in 2019/20 reflects the quality of the health services commissioned by them in 2018/19. The QP award will be based on measures that cover a combination of national and local priorities, and on delivery of the gateway tests, as described below.
3.1 Indicators

As communicated in the 2018/19 Planning Guidance, the structure of the Quality Premium is changing for the 2018/19 scheme year so as to incentivise moderation of demand for emergency care in addition to maintaining and or improving progress against key quality indicators. This section sets out the updated structure.

**Emergency Demand Management Indicators**
Value: £210m

<table>
<thead>
<tr>
<th>#</th>
<th>Indicator Name</th>
<th>Weighting</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>Type 1 A&amp;E attendances</td>
<td>50%</td>
</tr>
<tr>
<td>A2</td>
<td>Non elective admissions with zero length of stay</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>Non elective admissions with length of stay of 1 day or more</td>
<td>50%</td>
</tr>
</tbody>
</table>

**Quality Indicators**
Value: £68m

<table>
<thead>
<tr>
<th>#</th>
<th>Indicator Name</th>
<th>Weighting</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Early Cancer Diagnosis</td>
<td>17%</td>
</tr>
<tr>
<td>2</td>
<td>GP Access and Experience</td>
<td>17%</td>
</tr>
<tr>
<td>3</td>
<td>Continuing Healthcare</td>
<td>17%</td>
</tr>
<tr>
<td>4</td>
<td>Mental Health</td>
<td>17%</td>
</tr>
<tr>
<td>5</td>
<td>Bloodstream Infections</td>
<td>17%</td>
</tr>
<tr>
<td>6</td>
<td>RightCare*</td>
<td>15%</td>
</tr>
</tbody>
</table>

*CCGs can select one local indicator which will be worth 15% of the QP for the Quality Indicators. The indicator should be selected from the RightCare suite of indicators – as set out in the Commissioning for Value packs, focussing on an area of unwarranted variation locally which offers the potential for CCGs to drive improvement.

For each of these indicators the level of improvement required to trigger the reward is set out in the indicator specifications at Appendix 1.

3.2 Gateways

As in previous years, the Quality Premium includes three Gateways. The Finance and NHS Constitution Gateways have been revised to align with the Planning Guidance. See below for further details.
3.2.1 Quality Gateway

CCGs are responsible for the quality of the care and treatment that they commission on behalf of their population. NHS England reserves the right not to make any quality premium payments to a CCG in cases of serious quality failure, i.e. where it is identified that:

- a local provider has been subject to enforcement action by the Care Quality Commission; or
- a local provider has been flagged as a quality compliance risk and/or has requirements in place related to breaches of provider licence conditions; or
- a local provider has been subject to enforcement action based on a quality risk; and
- it has been identified through NHS England’s assessment of the CCG, in respect of the quality and governance elements of the Improvement and Assessment Framework, that the CCG is not considered to be making an appropriate, proportionate response with its partners to resolve the above quality failure; and
- this continues to be the position for the CCG at the end of year assessment.

As an alternative to withholding the Quality Premium in the circumstances above, NHS England may, at its discretion, make the Quality Premium available to the relevant CCG, if the CCG agrees to use the quality premium payment to help resolve the serious quality failure.

It is important that the Quality Premium and assessment processes are well aligned. Should the assessment process criteria with respect to quality failure change during this period, NHS England may amend the above criteria in order to maintain alignment with it, including if assessment criteria are introduced to identify quality failures within CCGs.

3.2.2 Financial Gateway

Effective use of public resources should be seen as an integral part of securing high-quality services. A CCG will not receive a quality premium if:

- in the view of NHS England, during the relevant financial year the CCG has not operated in a manner that is consistent with the obligations and principles set out in Managing Public Money\(^1\); or
- the CCG ends the relevant financial year with an adverse variance to their approved planned financial position\(^2\), or requires unplanned financial support to avoid being in this position; or
- it receives a qualified audit report in respect of the relevant financial year; or
- if relevant, the CCG does not meet the requirements set out in the Commissioner Sustainability Fund guidance.

---

\(^2\) CCGs are measured against all delegated budgets
3.2.3 NHS Constitution Gateway

The operation and focus of the NHS Constitution Gateway has been modified for 18/19. In particular, whilst it will continue to apply to the quality indicators, it will not apply to the new Emergency Demand Management indicators. Given the introduction of an emergency demand management element, and to remain aligned with the wider programmes, such as the Urgent and Emergency Care programme, we have suspended the operation of the tests relating to Ambulance response times and 4 Hour A&E. Finally, we have aligned the RTT test with the measure set out in the Refreshing NHS plans for 2018/19 guidance document.

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Reduction to Quality Premium</th>
</tr>
</thead>
<tbody>
<tr>
<td>The number of patients on an incomplete pathway not to be higher in March 2019 than in March 2018</td>
<td>50%</td>
</tr>
<tr>
<td>Maximum two month (62-day) wait from urgent GP referral to first definitive treatment for cancer</td>
<td>50%</td>
</tr>
</tbody>
</table>

In keeping with the need to keep the QP and CCG assessment processes well aligned, it is important to ensure alignment between the payment of the QP and the NHS Constitution Gateway. Should the measures in the NHS Constitution be updated, or expectations around the Commissioner or Provider Sustainability Funds change, NHS England may amend the above criteria in order to maintain alignment.

4 Calculation and use of Quality Premium payments

The maximum QP payment for a CCG will be expressed as £5 per head of population, calculated using the same methodology as for CCG running costs (This is in addition to a CCG’s main financial allocation and in addition to its running costs allowance).

For each measure where the identified threshold is achieved, the CCG will be eligible for the indicated percentage of the overall funding available to it. Where a CCG has failed to meet the requirements of the quality or financial gateways set out above, it will not receive a QP payment except where NHS England exercises its discretion with respect to the quality gateway.

It is planned that CCGs will be advised of the level of their QP award in quarter 3 of 2019/20 (with the exception of the Cancers diagnosed at early stage measure – please refer to Appendix 1 below). In order to maximise its ability to make the most effective use of the payment within 2019/20, each CCG should consider making plans for use of the payment in advance of this date, so that these plans can be implemented as soon as the level of award is confirmed.
QP payments can only be used for the purposes set out in regulations\(^3\). These state that QP payments should be used by CCGs to secure improvement in:

- the quality of health services; or
- the outcomes achieved from the provision of health services; or
- reducing inequalities between patients, in terms of their ability to access health services or the outcomes achieved.

CCGs may utilise the QP payment with other organisations to deliver the improvements above where appropriate wider powers are available for the use of the funding in this manner.

Each CCG is required\(^4\) to publish an explanation of how it has spent a QP payment.

---

\(^3\) The National Health Service (Clinical Commissioning Groups-Payments in Respect of Quality) Regulations 2013 (S.I. 2013/474)

\(^4\) Section 223K(7) of the NHS Act 2006
## Appendix 1: Quality Premium measures (2018/19 Scheme)

<table>
<thead>
<tr>
<th>Quality Premium Measure</th>
<th>Emergency demand planning</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thresholds</strong></td>
<td>This is split into two parts, each weighted 50%:</td>
</tr>
<tr>
<td><strong>Part a)</strong></td>
<td>Actual number of Type 1 A&amp;E attendances to be no greater than the planned number of Type 1 A&amp;E attendances. AND Actual number of non-elective admissions with LOS =0 to be no greater than the planned number of non-elective admissions with LOS =0.</td>
</tr>
<tr>
<td><strong>Part b)</strong></td>
<td>Actual number of non-elective admissions with LOS of 1 day or more to be no greater than the planned number of non-elective admissions with LOS of 1 day or more.</td>
</tr>
<tr>
<td><strong>Value</strong></td>
<td>100% of the Demand Management Indicators</td>
</tr>
<tr>
<td><strong>Rationale</strong></td>
<td>The Planning Guidance 2018/19 states that CCGs along with providers will need to take action to moderate urgent care demand. CCG plans for non-elective demand must also be realistic and agreed with providers in order to support access to, and deliver, high quality care for patients with urgent and emergency need. In support of the above, this Quality Premium indicator is contingent on CCGs having realistic emergency demand plans agreed with providers and delivering against them in 2018/19.</td>
</tr>
<tr>
<td><strong>Technical Definition</strong></td>
<td>There will be two parts. Part a) will include two non-elective demand measures and part b) a third non-elective demand measure.</td>
</tr>
<tr>
<td><strong>Part a)</strong> [50% weighting]</td>
<td>The reward on offer will be earned when a CCG’s:</td>
</tr>
<tr>
<td></td>
<td>- Total number of type 1 A&amp;E attendances for 2018/19 is no greater than their total planned number of type 1 A&amp;E attendances in 2018/19. AND</td>
</tr>
<tr>
<td></td>
<td>- Total number of actual non-elective admissions with LOS =0 days in 2018/19 is no greater than their total planned number of non-elective admissions with LOS = 0 days in 2018/19.</td>
</tr>
<tr>
<td></td>
<td>These will be measured as simply the difference between actual and plan</td>
</tr>
</tbody>
</table>
e.g. [2018/19 actual attendances] - [2018/19 planned attendances]

The Quality Premium methodology document provided to CCGs later in the year will lay out further details including the application of confidence limits to plans (to account for the natural variability of non-elective activity).

Type 1 A&E attendances are taken directly from SUS with the applied restrictions:
- AEA_Attendance_Category <> 2
- AEA_Department_Type IN('01', '1')

A Non-Elective Admission is one that has not been arranged in advance. Specific Acute Non-Elective Admissions may be an emergency admission or a transfer from a Hospital Bed in another Health Care Provider other than in an emergency.

It will be measured in SUS as the number of hospital provider spells for which:
- Der_Management_Type is ‘EM’ or ‘NE’ (Where ‘EM’ = Emergency and ‘NE’ = Non-Elective)
- Treatment function maps to Specific Acute
- the date of admission is the same as the discharge date

This is the E.M.11a measure in the Joint Technical Definitions for Performance and Activity 2018/19:


Part b) [50% weighting]

The reward on offer will be earned when a CCG’s:
- Total number of actual non-elective admissions with LOS >=1 days in 2018/19 is no greater than their total planned number of non-elective admissions with LOS >=1 days in 2018/19.

This will be measured as simply the difference between actual and plan i.e. [2018/19 actual admissions] - [2018/19 planned admissions].

The Quality Premium methodology document provided to CCGs later in the year will lay out further details including the application of confidence limits to plans (to account for the natural variability of non-elective activity).

A Non-Elective Admission is one that has not been arranged in advance. Specific Acute Non-Elective Admissions may be an emergency admission or a transfer from a Hospital Bed in another Health Care Provider other than in an
emergency.

It will be measured in SUS as the number of hospital provider spells for which:

- Der_Management_Type is ‘EM’ or ‘NE’ (Where ‘EM’ = Emergency and ‘NE’ = Non-Elective)
- Treatment function maps to Specific Acute
- the date of admission is not the same as the discharge date

This is the E.M.11b measure in the Joint Technical Definitions for Performance and Activity 2018/19:


### Data Source

**Parts a & b**

**Actual Activity:**
The underlying data are sourced from the SUS+ SEM extracts which are updated within the National Commissioning Data Repository three working days after the SUS+ inclusion date each month. Additional adjustments are applied by Operational Information for Commissioning (OIC) to correct for gaps and duplicates at provider level where these discrepancies are considered to relate to data quality issues with provider submissions. Unadjusted data are also available for comparison.

**Plan Activity:**
CCG 2018/19 plans submitted via the Unify2 template in the final round of the planning process for 2018/19.

### Published Frequency & Timeliness

Performance against this indicator will be assessed after the end of 2018/19 and payment where applicable will be made in Quarter 3 2019/20.
## Quality Premium Measure

<table>
<thead>
<tr>
<th>Threshold</th>
<th>Cancers diagnosed at early stage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>To earn this portion of the Quality Premium, CCGs will need to either:</td>
</tr>
<tr>
<td></td>
<td>1. Demonstrate a 4 percentage point improvement in the proportion of cancers (specific cancer sites, morphologies and behaviour*) that are diagnosed at stages 1 and 2 in the 2018 calendar year compared to the 2017 calendar year.</td>
</tr>
<tr>
<td></td>
<td>Or</td>
</tr>
<tr>
<td></td>
<td>2. Achieve greater than 60% of all cancers (specific cancer sites, morphologies and behaviour*) that are diagnosed at stages 1 and 2 in the 2018 calendar year.</td>
</tr>
</tbody>
</table>

## Value
17% of Quality Indicators

## Rationale
Cancer survival rates in England have never been higher, but we know that we often lag behind the highest performing countries in the world in international comparisons. We also know that the earlier cancer is diagnosed, the more likely it is to be successfully treated, and survival rates can be dramatically improved. The independent cancer taskforce, in their report *Achieving World-Class Cancer Outcomes*, published in July 2015, set an ambition for the NHS that 62% of all cancers with known stage at diagnosis would be diagnosed at stages 1 and 2 by 2020. Achieving this target will require every CCG to focus on and make significant improvement in early stage diagnoses.

Specific public health interventions, such as screening programmes and public information campaigns can aim to improve rates of early diagnosis. Supporting clinicians to spot cancers earlier and greater GP access to diagnostic and specialist advice were outlined in the Five Year Forward View as key planks of improving our diagnostic strategies. In addition, NICE published new guidance on appropriate referral for suspected cancer in 2015, which lowered the threshold of risk for symptoms suggestive of cancer to trigger an urgent referral for suspected cancer to 3%, with the aim of diagnosing more cancers at an early stage.

An indicator on the proportion of cancers diagnosed at an early stage is therefore a useful measure for assessing improvement in early diagnosis and ultimately cancer survival. Improving cancer survival is one of the three key ambitions outline in *Achieving World-Class Cancer Outcomes*.

Thresholds have been set based on levels of improvement previously seen amongst high-performing CCGs and felt to be
achievable for the majority of CCGs.

| Technical Definition | New cases of cancer diagnosed at stage 1 and 2 as a proportion of new cases of cancer diagnosed (specific cancer sites, morphologies and behaviour*).

**Numerator:** Cases of cancer diagnosed at stage 1 or 2, for the specific cancer sites, morphologies and behaviour*.

**Denominator:** All new cases of cancer diagnosed at any stage or unknown stage, for the specific cancer sites, morphologies and behaviour*.

*invasive malignancies of breast, prostate, colorectal, lung, bladder, kidney, ovary, uterus, non-Hodgkin lymphomas, and invasive melanomas of skin. |

The most recent data is available at: [http://www.ncin.org.uk/publications/survival_by_stage](http://www.ncin.org.uk/publications/survival_by_stage)  
The quarterly data referenced is available here: [http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/cancer_outcome_metrics](http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/cancer_outcome_metrics) |

| Published Frequency & Timeliness | Data will be a rolling window of one year's worth of data. The data will be lagged by 12 months.  
Due to the fact that the data is lagged by 12 months, payment of the Quality Premium award will be made in two stages. Details of this will be provided in the Assessment Methodology which will be circulated to CCGs following the QP performance year. |
<table>
<thead>
<tr>
<th>Quality Premium Measure</th>
<th>Overall experience of making a GP appointment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Threshold</strong></td>
<td>To earn this portion of the Quality Premium, CCGs will need to demonstrate in the July 2019 publication, either:</td>
</tr>
<tr>
<td></td>
<td>• Achieve a level of 85% of respondents who said they had a good experience of making an appointment, or;</td>
</tr>
<tr>
<td></td>
<td>• Achieve a 3 percentage point increase from July 2018 publication on the percentage of respondents who said they had a good experience of making an appointment.</td>
</tr>
<tr>
<td><strong>Value</strong></td>
<td>17% of Quality Indicators</td>
</tr>
<tr>
<td><strong>Rationale</strong></td>
<td>The GP Patient Survey (GPPS) seeks the views of 2.4 million people every year about their experience of GP services and results are published at GP practice level.</td>
</tr>
<tr>
<td></td>
<td>The survey gives patients the opportunity to provide feedback on a number of aspects of their experience of their GP practice, and provides a rich source of quantitative data on patients’ experiences of the access and quality of care they receive.</td>
</tr>
<tr>
<td></td>
<td>Access to GP services and, in particular, the ease of making an appointment is a key measure of patient experience and affects the wider healthcare system as patients who find it difficult to access GP services may seek care through emergency services inappropriately. Q18 (“Overall, how would you describe your experience of making an appointment?”) of the GP Patient Survey (GPPS) is the “litmus test” indicator in this regard.</td>
</tr>
<tr>
<td></td>
<td>Attaching a Quality Premium payment will also ensure that the profile and importance of insight about patient experience is underlined and it will incentivise the wider system to review and learn from the findings of the GPPS.</td>
</tr>
</tbody>
</table>
**Technical Definition**

Question 18: Overall, how would you describe your experience of making an appointment?

- Very good
- Fairly good
- Neither good nor poor
- Fairly poor
- Very poor

**Numerator:** the weighted number of people answering ‘very good’ or ‘fairly good’ to question 18 of the GP Patient Survey.

This is expressed as \( \Sigma_k (wt_{new_k}) \) where \( k = 1, \ldots, p \) which are all respondents who answer question 18 with either answering ‘very good’ or ‘fairly good’.

**Denominator:** the total weighted number of people who answer question 18 of the GP Patient Survey. This is expressed as \( \Sigma_j (wt_{new_j}) \) where \( j = 1, \ldots, q \) which are all respondents who answer question 18.

**Weighting:**

A weight is applied to construct the indicator. The GP Patient Survey includes a weight for non-response bias (\( wt_{new} \)). This adjusts the data to account for potential differences between the demographic profile of all eligible patients in a practice and the patients who actually complete the questionnaire. The non-response weighting scheme has been developed by Ipsos MORI, incorporating elements such as age and gender of the survey respondent as well as factors from the area where the respondent lives such as level of deprivation, ethnicity profile, ACORN classification and so on, which have been shown to impact on non-response bias within the GP Patient Survey. Further information on the current weighting scheme can be found in the survey’s technical annex: [http://gp-survey-production.s3.amazonaws.com/archive/2015/July/14-008280-01_Technical%20Annex%202014-2015.pdf](http://gp-survey-production.s3.amazonaws.com/archive/2015/July/14-008280-01_Technical%20Annex%202014-2015.pdf)

**Data Source**

Data for this indicator is from the GP Patient Survey. This survey is commissioned by NHS England and is conducted by the independent survey organisation Ipsos MORI.

**Published Frequency & Timeliness**

Published annually in July representing data collection from January to March.
### Quality Premium Measure

<table>
<thead>
<tr>
<th><strong>Threshold</strong></th>
<th><strong>NHS Continuing Healthcare (NHS CHC)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Part a)</strong> worth 50%</td>
<td>To achieve the Quality Premium for this part, CCGs must ensure that in more than 80% of cases with a positive NHS CHC Checklist, the NHS CHC eligibility decision is made by the CCG within 28 days from receipt of the Checklist (or other notification of potential eligibility).</td>
</tr>
<tr>
<td><strong>Part b)</strong> worth 50%</td>
<td>To achieve the Quality Premium for this part, CCGs must ensure that less than 15% of all full NHS CHC assessments take place in an acute hospital setting.</td>
</tr>
</tbody>
</table>

For both indicators, achievement of the Quality Premium is measured in aggregate across the full year 2018/19.

### Value

17% of Quality Indicators
Part a) The time that elapses between the Positive Checklist (or, where no Checklist is used, other notification of the need for a full assessment) being notified to the CCG and the funding decision being made should, in most cases, not exceed 28 days.

CCGs should make all reasonable efforts to ensure the required information or participation is made available within 28 days. This should include developing protocols with services likely to be regularly involved in NHS Continuing Healthcare eligibility processes that reflect the need for information or participation within 28 days. Where the CCG commissions the service from which information or participation is regularly required, it may be appropriate to consider placing such expectations within the specification for the relevant service.

Part b) It is preferable for eligibility for NHS Continuing Healthcare to be considered after discharge from hospital when the person’s long-term needs are clearer, and for NHS-funded services to be provided in the interim. This might include therapy and/or rehabilitation, if that could make a difference to the potential further recovery of the individual in the following few months. It might also include intermediate care or an interim package of support in an individual’s own home or in a care home.

It should always be borne in mind that assessment of eligibility that takes place in an acute hospital may not always reflect an individual’s capacity to maximise their potential. This could be because, with appropriate support, that individual has the potential to recover further in the near future. It could also be because it is difficult to make an accurate assessment of an individual’s needs while they are in an acute services environment. Anyone who carries out an assessment of eligibility for NHS Continuing Healthcare should always consider whether there is further potential for rehabilitation and for independence to be regained, and how the outcome of any treatment or medication may affect ongoing needs.

In order to address this issue and ensure that unnecessary stays on acute wards are avoided, there should be consideration of whether the provision of further NHS-funded services, or those funded jointly with Local Authorities, is appropriate. This might include therapy and/or rehabilitation, if that could make a difference to the potential of the individual in the following few months. It might also include intermediate care or an interim package of support in an individual’s own home or in a care home. In such situations, assessment of eligibility for NHS Continuing Healthcare should usually be deferred until an accurate assessment of future needs can be made. The interim services (or appropriate alternative interim services if needs change) should continue in place until the determination of eligibility for NHS Continuing Healthcare has taken place. There must be no gap in the provision of appropriate support to meet the individual’s needs.
| Technical Definition | Part a) In 80% of cases with a positive NHS CHC Checklist, the NHS CHC eligibility decision is made by the CCG within 28 days from notification of the Checklist (or other notification of the need for a full assessment).

This applies to new referrals and not reviews of existing NHS CHC cases or Previously Unassessed Periods of Care cases.

**Elapsed time calculation:**
Clock starts: 28 days referral time starts from the date the CCG is notified that full consideration for NHS CHC is required i.e. a positive checklist or other notification of potential eligibility.

Clock stops: At the date the CCG makes a decision on eligibility.

**Numerator:** Number of NHS CHC eligibility decisions where the CCG makes a decision within 28 days of being notified of the need for full consideration for NHS CHC i.e. a positive checklist or other notification of potential eligibility (sum of quarterly data).

**Denominator:** Total number of NHS CHC eligibility decisions made within the financial year (sum of quarterly data).

This will then provide a percentage of NHS CHC referrals that have been completed within 28 days.

The collection method uses both in-built data validations at point of entry and data quality checking post collection. The data collection is accompanied by guidance and definitions.

Part b)

**Numerator:** Number of full comprehensive NHS CHC assessments completed whilst the individual was in an acute hospital in the relevant financial year (sum of quarterly data).

**Denominator:** Total number of full NHS CHC assessments completed in the financial year (sum of quarterly data). This will then provide a percentage of full NHS CHC assessments that were completed in an acute hospital in the relevant financial year (sum of quarterly data).

The collection method uses both in-built data validations at point of entry and data quality checking post collection. The data collection is accompanied by guidance and definitions.

<p>| Data Source | NHS England NHS CHC report (the collection is presently covered by Burden Advice and Assessment Service (BAAS) approval until 31st March 2020). The BAAS reference codes are R01108/ SCCI2117. |
| Published Frequency &amp; Timeliness | Quarterly data collection commenced in Q1 17/18. Q1 data was published on 14th September 2017 (11 weeks after quarter end). Q2 data was published on 14th December 2017 (11 weeks). Q3 data was published on 8th February 2018 (5 weeks after quarter end). Frequency from then onwards will be the second Thursday of the second month after the reporting quarter’s end. |</p>
<table>
<thead>
<tr>
<th>Quality Premium Measure</th>
<th>Mental Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>Threshold</td>
<td>This Quality Premium measure consists of three indicators from which one will be chosen based upon the inequality most pertinent to a given CCG.</td>
</tr>
<tr>
<td></td>
<td>a) Out of area placements (OAPs).</td>
</tr>
<tr>
<td></td>
<td>b) Equity of Access and outcomes in Improving Access to Psychological Therapies (IAPT) services.</td>
</tr>
<tr>
<td></td>
<td>c) Improve inequitable rates of access to Children &amp; Young People’s Mental Health Services.</td>
</tr>
<tr>
<td></td>
<td>The CCG and NHSE Regional Team will agree the indicator most pertinent to the CCG. Where a different menu choice is agreed in Year 2, for example due to a CCG merger, Year 1 thresholds will apply and baselines may need to be updated.</td>
</tr>
<tr>
<td></td>
<td>Only one element will be applied to a given CCG and so each element will be worth 100% of the Quality Premium payment available for this indicator.</td>
</tr>
<tr>
<td></td>
<td>Each element of the Quality Premium has specific thresholds as follows:</td>
</tr>
<tr>
<td>Part a) OAPs:</td>
<td>a one third year-on-year reduction in the number of inappropriate adult OAPs for non-specialist adult acute care.</td>
</tr>
<tr>
<td></td>
<td>Specifically, the total number of bed days relating to inappropriate out of area placements to have reduced by 33% each year from the baseline value.</td>
</tr>
<tr>
<td></td>
<td>N.B. —this measure refers to adult acute, older adult acute, and Psychiatric Intensive Care Unit (PICU) beds only. In future years there is likely to be an expectation to reduce OAPs for all CCG-commissioned beds (e.g. Rehabilitation). A national definition of OAPs is included in guidance.</td>
</tr>
<tr>
<td>Part b) Equity of Access and outcomes in IAPT services</td>
<td>I. Recovery rate of people accessing IAPT services identified as Black, Asian and minority ethnic (BAME); improvement of at least 5 percentage points each year or to the same level as white British (for the CCG), whichever is smaller.</td>
</tr>
<tr>
<td></td>
<td>AND</td>
</tr>
</tbody>
</table>
|                         | II. Proportion of people accessing IAPT services aged 65+; to increase to at least 50% of the proportion of adults aged 65+ in the local population or by at least 33%, whichever is
greater in Year 1.

For Year 2, to increase to at least 70% of the proportion of adults aged 65+ in the local population, or where 70% has already been achieved or exceeded by the end of Year 1, to not decrease in Year 2.

E.g. for Year 2, if 60% of CCG adult population is aged over 65 then 42% (70% of 60%) of those accessing IAPT should be aged over 65.

It is required that both elements must be met in order to meet this indicator.

Part c) Improved Access to Children & Young People’s Mental Health Services

The required performance in Year 1 is whichever is the greater of:

I. At least a 14% increase in the number of individual children and young people aged under 18 with a diagnosable Mental Health condition receiving treatment by NHS funded community services when they need it in Year 1 based on 2016/17 baseline.

OR

II. The increase in activity necessary to enable 32% of children and young people aged under 18 with a diagnosable Mental Health condition to receive treatment in NHS funded community services when they need it in Year 1.

The required performance in Year 2 is whichever is the greater of:

I. The increase in activity necessary to enable 34% of children and young people aged under 18 with a diagnosable Mental Health condition to receive treatment in NHS funded community services when they need it in Year 2.

OR

II. Where a CCG has achieved 34% in Year 1, achieve the same percentage point improvement as achieved in Year 1.

Value 17% of the Quality Premium

CCG’s and their NHSE Regional Teams will agree the indicator to be applied to that CCG, based upon the inequality most pertinent to that CCG.

Rationale The Five Year Forward View for Mental Health placed a particular
focus on tackling inequalities. Addressing this, a mandatory Mental Health element of the Quality Premium will focus on a number of key inequalities, allowing for the targeting of particular needs pertinent to local health economies and enabling CCGs to draw together resources in order to address local priorities.

The Quality Premium will provide significant incentive for CCGs and their local partners to collaborate in pursuit of improvements in the quality of mental health outcomes.

Based on NHS England’s interpretation of a CCG’s most pertinent needs in this area, this element of QP will be addressed against one of the following inequalities:

a) OAPs
People requiring acute mental health care should always receive evidence based treatment, close to home and in the least restrictive setting. Unfortunately we know that too many acutely unwell people, who require inpatient care, are sent far away from their friends and families at this time when they are particularly vulnerable.

Evidence shows that people receiving care out of area have far worse outcomes than those receiving care locally and have a far higher incidence of suicide. Furthermore, OAPs are far more costly to provide which means that public funding is not being used to best effect. This is, of course, unacceptable, and Implementing the Five Year Forward View for Mental Health agreed to the Mental Health Taskforce recommendation that inappropriate OAPs for non-specialist acute mental health care should be eliminated.

Some areas have already achieved this ambition, but there are still high levels of variation across the country. This is why OAPs are being included as a measure in the Quality Premium.

b) Equity of Access and outcomes in IAPT services
Improving access is a priority in the Five Year Forward View for Mental Health: by 2020/21 at least 25% of people with common MH conditions should access services each year. In parallel, quality should be maintained and developed; including meeting existing waiting times and recovery standards, and improving access and outcomes for all adults.

We know that people from Black, Asian and Minority Ethnic (BAME) communities can experience poorer outcomes from services than people who identify themselves as White British. In the most recently available national data (Quarter 4 2015/16) the recovery rates for people from Black Asian and Minority groups were as much as 13.6 percentage points lower than the rate for people identified as White British.
In addition, older people are under-represented in services, not accessing them as readily as people who are under 65 years of age. The percentage of over 65s completing a course of treatment is around 7% nationally, which is lower than the equivalent proportion of the adult population at approximately 13%.

Service providers and commissioners should be taking action to ensure equity of access to and outcomes from IAPT services to people irrespective of any protected characteristics (as defined under the Equalities Act 2010) in line with their Public Sector Equalities Duties (PSED). They must also pay due regard to the need to reduce health inequalities between patients in access to and outcomes from IAPT services.

There are examples of good practice in making IAPT services serve their whole population equally, and improving access for older people and outcomes for people from Black and Minority Ethnic groups is a good step towards this goal.

c) Improved rates of access to Children & Young People’s Mental Health services

Children and young people are a priority group for mental health promotion and prevention, and the Five Year Forward View for Mental Health calls for the Future in Mind recommendations to be implemented in full. Early intervention and quick access to good quality care is vital – especially for children and young people. Waiting times should be substantially reduced, significant inequalities in access should be addressed and support should be offered while people are waiting for care.

One in ten children has a diagnosable MH disorder. This can range from short spells of depression or anxiety through to severe and persistent conditions that can isolate, disrupt and frighten those who experience them. Mental Health problems in young people can result in lower educational attainment (for example, children with conduct disorder are twice as likely as other children to leave school with no qualifications) and are strongly associated with behaviours that pose a risk to their health, such as smoking, drug and alcohol abuse and risky sexual behaviour.

Despite recognition that early intervention can be highly cost effective, a significant treatment gap persists. The last UK epidemiological study suggested that, at that time, less than 25% – 35% of those with a diagnosable Mental Health condition accessed support. Compounding this, data from the NHS benchmarking network and recent audits year on year reveal increases in referrals and waiting times, with providers reporting increased complexity and severity of presenting problems. This indicator seeks to address this inequitable treatment gap by improving access.
Addressing the difficulties in accessing the help they need NHSE has committed to helping at least 70,000 more children and young people each year to access high-quality, evidence based Mental Health care when they need it by 2020/21.

An increase of 14% accessing treatment is consistent with the national real terms improvement required to move 12 months ahead of the national trajectory, set out in *Implementing the Five Year Forward View for Mental Health*.

### Technical Definition

**a) OAPs** – a 33% or greater year-on-year reduction in inappropriate OAPs is required to receive the QP.

For Year 1 the total number of bed days people sent inappropriately out of area to have reduced by 33% from the baseline value.

For Year 2 the total number of bed days people sent inappropriately out of area to have reduced by a further 33% from the baseline value (i.e. 66% reduction from baseline).

**Numerator**: Total number of bed days people sent inappropriately out of area in Q4 Year 1 and Q4 Year 2.

**Denominator**: No denominator – measure is a count

**Baseline**: Maximum quarterly number of bed days of people sent inappropriately out of area from the 10 rolling quarterly periods between Jan 2017 and Dec 2017[^5]

**Source**: Clinical Audit Platform (CAP) collection on OAPs, available since December 2016 [http://content.digital.nhs.uk/oaps](http://content.digital.nhs.uk/oaps)

**b) Equity of Access and outcomes in IAPT services**

Satisfactory performance against both components required to receive the QP.

There are two components of the IAPT indicator, which is applicable in both Year 1 and Year 2, enabling both short and medium term improvement activity:

- **BAME Recovery**: For Year 1, the recovery rate of people accessing IAPT services identified as BAME to show an improvement of at least 5 percentage points (against Q4

[^5]: In acknowledgement that increases have been observed in the data due both to improved reporting and as a result of the exclusion of pre-existing OAPs prior to 17th October 2016 it is expected that this approach will support the formulation of an appropriate baseline against which to assess CCG performance.
2016/17) or increase to the same level as white British (for the CCG), whichever is smaller, in Q4 Year 1.

For Year 2, the recovery rate of people accessing IAPT services identified as BAME to show an improvement of at least 5 percentage points (against Q4 Year 1) or increase to the same level as white British (for the CCG), whichever is smaller, in Q4 Year 2.

Numerator: Number of people from BAME groups who have finished treatment having attended at least two treatment contacts and are moving to recovery (those who at initial assessment achieved “caseness” and at final session did not).

Denominator: Number of people from BAME groups who have finished treatment having attended at least two treatment contacts and coded as discharged) minus (The number of people who have finished treatment not at clinical caseness at initial assessment).

Source: IAPT MDS, aggregated information necessary for this calculation, available quarterly since December 2016 http://content.digital.nhs.uk/iaptreports

b. Older People’s Access
   For Year 1, whichever is the greater of:
   The proportion of people accessing IAPT services aged 65+ to increase to at least 50% of the proportion of adults aged 65+ in the local population in Q4 Year 1,
   OR

   The proportion of people accessing IAPT services aged 65+ to have increased by at least 33% (against Q4 2016/17), in Q4 Year 1.

   For Year 2:
   The proportion of people accessing IAPT services aged 65+ to increase to at least 70% of the proportion of adults aged 65+ in the local population in Q4 Year 2,
   OR,

   Where 70% has already been achieved or exceeded by Q4 Year 1 to achieve the same % point improvement in Q4 Year 2 as that achieved in Q4 Year 1.

Numerator: number of people entering treatment to IAPT Services aged 65+ as a proportion of total number of people aged 18+ entering treatment to IAPT Services.
Denominator: Number of people aged 65+ in the local population as a proportion of total number of people aged 18+ in the local population⁶.

Source: IAPT MDS, aggregated information necessary for this calculation, available quarterly since December 2016. ONS population data.
http://content.digital.nhs.uk/iaptreports

Compliance is defined as achieving both components.

c) CYP- MH Access – in order to achieve the QP, the required performance in Year 1 is whichever is the greater of:

a. At least a 14% increase in the number of individual children and young people aged under 18 with a diagnosable Mental Health condition receiving treatment by NHS funded community services when they need it in Year 1.

Numerator: The number of children and young people aged under 18 with a diagnosable MH condition receiving treatment in NHS funded community services in (whole year) Year 1.

Denominator: None, the measure is a count

Baseline: total number of individual children and young people under 18 with a diagnosable MH condition receiving treatment in NHS funded community services in (whole year) 2016/17.

Source:

Numerator: Due to the experimental nature of these indicators the underlying data will initially be published as part of NHS Digital's Supplementary Information pages http://content.digital.nhs.uk/suppinfopages) Specifically:
http://content.digital.nhs.uk/7572 ("Children and young people mental health indicators")

Baseline: The baseline figure is taken from indicator 2a as signed off as part of the 2017-2019 operational and contracting planning round. Please see Annex E

⁶ assessment of CCG performance will be informed by available and contemporaneous population estimates provided by ONS:
b. The increase in activity necessary to enable 32% of children and young people aged under 18 with a diagnosable MH condition to receive treatment in NHS funded community services when they need it in Year 1.

**Numerator:** The number of children and young people aged under 18 with a diagnosable MH condition receiving treatment in NHS funded community services in the whole year (Year 1).

**Denominator:** Total number of individual children and young people under 18 with a diagnosable MH condition i.e. the estimated prevalence of mental ill health in the population.

**Source:**

**Numerator:** Due to the experimental nature of these indicators the underlying data will initially be published as part of NHS Digital's Supplementary Information pages. [http://content.digital.nhs.uk/suppinfofiles](http://content.digital.nhs.uk/suppinfofiles)

Specifically: [http://content.digital.nhs.uk/7572](http://content.digital.nhs.uk/7572) (“Children and young people mental health indicators”)


The required performance in Year 2 is:

I. The increase in activity necessary to enable 34% of children and young people aged under 18 with a diagnosable Mental Health condition to receive treatment in NHS funded community services when they need it in Year 2.

OR

II. Where a CCG has achieved 34% in Year 1, to show the same % point improvement in Year 2 as achieved in Year 1.

**Numerator:** Total number of individual children and young people aged under 18 receiving treatment by NHS funded community services in (whole year) Year 2

**Denominator:** Total number of individual children and young people aged under 18 with a diagnosable MH condition.
**OFFICIAL**

<table>
<thead>
<tr>
<th>people aged under 18 with a diagnosable mental health condition in (whole year) Year 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline (for II.):</strong> total number of individual children and young people under 18 with a diagnosable MH condition receiving treatment in NHS funded community services.</td>
</tr>
</tbody>
</table>

**Source:**

**Numerator:** Mental Health Services Dataset v1.0

http://digital.nhs.uk/mhdsd

**Denominator:** The baseline figure is taken from indicator 2a as signed off as part of the 2017-2019 operational and contracting planning round. Please see Annex E


**Baseline:** This estimated prevalence value is taken from indicator 2b as signed off as part of the 2017-2019 operational and contracting planning round. Please see Annex M.

This Quality Premium measure consists of three parts:

Part A) reducing gram negative blood stream infections (BSI) across the whole health economy.

Part B) reduction of inappropriate antibiotic prescribing for urinary tract infections (UTI) in primary care.

Part C) sustained reduction of inappropriate prescribing in primary care.

The weighting for the three measures is as follows:

**Part A = 45% Part B= 20% Part C= 35%:**
- **Part A i)** will be worth 30%
- **Part A ii)** will be worth 15% payable as 10% for Q2 and 5% for Q3
- **Part B i)** will be worth 20%
- **Part C i)** will be worth 10%. **Part C ii)** will be worth 25%

Payment must be considered individually for each component of the QP as each part supports improvement within different areas which, individually and collectively support the overarching ambition.

Targets associated with each element have been reviewed for 2018/19.

**Part A) reduction in the number of gram negative blood stream infections across the whole health economy.**

i. The reduction target in all *E coli* BSI reported at CCG level based on 2016 performance data remains in 2018/19. A 10% reduction now attracts 20% of the weighting. Two extra milestones of 15% and 20% reductions have been added (maximum 30% weighting). See partial payment table below:

<table>
<thead>
<tr>
<th>Reduction against baseline</th>
<th>% QP available</th>
</tr>
</thead>
<tbody>
<tr>
<td>20% +</td>
<td>30%</td>
</tr>
<tr>
<td>15 – 19.99%</td>
<td>25%</td>
</tr>
<tr>
<td>10 – 14.99%</td>
<td>20%</td>
</tr>
<tr>
<td>&lt;10%</td>
<td>0%</td>
</tr>
</tbody>
</table>

ii. Collection and reporting of a core primary care data set for all *E coli* cases is desirable, however the minimum requirement is 100% of all *E coli* BSI cases in Q2 (10% weighting) and 50% of all *E coli* BSI cases in Q3 (5% weighting) in 2018/19. This data should be used to identify local healthcare associated risk factors that inform local intervention strategy; data entry onto the PHE DCS is desirable but
Annex B

not compulsory.

**Part B) reduction of inappropriate antibiotic prescribing for UTI in primary care.**

i. A 30% reduction (or greater) in the number of Trimethoprim items prescribed to patients aged 70 years or greater on baseline data (June15-May16) (20% weighting)

**Part C) sustained reduction of inappropriate prescribing in primary care.**

i. Items per Specific Therapeutic group Age-Sex Related Prescribing Unit (STAR-PU) must be equal to or below England 2013/14 mean performance value of 1.161 items per STAR-PU (10% weighting).

ii. Additional reduction in Items per Specific Therapeutic group Age-Sex Related Prescribing Unit (STAR-PU) equal to or below 0.965 items per STAR-PU. This threshold is additional for 2018/19 (25% weighting).

<table>
<thead>
<tr>
<th>Value</th>
<th>17% of Quality Indicators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rationale</td>
<td>Work to develop and deliver this Quality Premium directly responds to the ambitions set by Government following the O’Neill Review on Antimicrobial Resistance (May, 2016). These ambitions include a:</td>
</tr>
<tr>
<td></td>
<td>• 50% reduction of healthcare associated Gram Negative Bloodstream Infections (GNBSIs) by 2020/21</td>
</tr>
<tr>
<td></td>
<td>• 50% reduction of the number of inappropriate antibiotic prescriptions by 2020/21.</td>
</tr>
<tr>
<td></td>
<td>It also enables work (across the ALBs) to support the UK 5 Year AMR Strategy (2013-2018), which states that there are few public health issues of greater importance than antimicrobial resistance (AMR) in terms of impact on society. Infections are increasingly developing that cannot be treated and the rapid spread of multi-drug resistant bacteria means that we could be close to reaching a point where it is not possible to prevent or treat everyday infections or diseases.</td>
</tr>
<tr>
<td></td>
<td>This work will support the other clinical priority areas, across NHS England and NHS Improvement, particularly through supporting the Sepsis agenda and by informing improvements in community care. It will assist Sustainability and Transformation Planning footprints to develop and deliver Sustainability and Transformation Plans - for which patient safety, and AMR specifically, are included as key priority areas – and local AMR plans (which are being lead and supported by PHE).</td>
</tr>
</tbody>
</table>

**Part A) reducing gram negative blood stream infections across the whole health economy**

Healthcare-associated Gram-negative bacteraemias (GNB) bloodstream infections
infections pose a significant health risk and threat to patient safety. They include infections caused by *Escherichia coli*, and *Pseudomonas aeruginosa*. Rates of bacteraemia caused by GNB vary depending on the bacterial species:

- Mandatory surveillance of *Escherichia coli* (*E*.coli) has indicated an alarming rise in rates of *E*. coli bacteraemia (60.4 to 66.2 per 100,000 population from 2012-2015).
- Rates of *Pseudomonas* spp. and *Stenotrophomonas* spp. bacteraemia have decreased steadily. (6.9 to 6.2 per 100,000 and 1.3 to 0.8 per 100,000, respectively, from 2007-2014).
- Rates of carbapenemase-producing enterobacteriaceae (CPE) are also increasing within the UK.
- Health care acquired infections (HCAIs) associated with multi-drug resistant (MDR) Gram-negative species are of utmost importance due to the difficulties in treatment associated with the limited number of effective antibiotics.

*E*.coli bacteraemia is the largest most prevalent group of GNBSI which supports the QP’s focus on these bacteraemia over the next 2 years. The reporting of *E*.coli BSI is already mandatory (via the PHE DCS system) and this provides data on which to establish a baseline and set reduction targets for 2017/18. Reduction targets have been revised for 2018/19, and the current 10% reduction remains with additional stretch targets attracting a greater weighting of the overall QP. Reduction in other GNBSI should be considered in future years when systems should have been established to capture baseline data.

**Part B) reduction of inappropriate antibiotic prescribing for Urinary Tract Infections (UTI) in primary care.**

The age group with the highest rates of *E*. coli bacteraemia in England were observed amongst the elderly (75 years and over) with 402.9 and 313.5 reports per 100,000 population for males and females respectively.

The PHE enhanced data set reported to Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infections (ARHAI) 24-14 (01) for *E* coli BSI (including 3 months of data from 38 acute trusts Nov 2012-Jan 2013, reporting on 891 cases) stated that 50% of cases related to the urogenital tract and in these, 72% occurred in patients >65years, and 64% of patients had reported at least one UTI in the previous 12 months. This supports the focus of this element of the QP.

The report states that: *is it clear that a significant proportion of the rise may be due to patients being prescribed inappropriate antibiotics, resulting in relapsing infections. It is important that antimicrobial prescribing is appropriate and effective. However, there remains a difficult balance between the clinical management of UTIs and the empiric prescribing of broad-spectrum antimicrobials due to increasing resistance to narrow spectrum antibiotics which limits available treatment options.*
Ongoing mandatory surveillance continues to identify previous UTIs as a key risk factor. This indicator would work to increase the appropriate use of nitrofurantoin as 1st line choice for the empirical management of UTI in primary care settings, and support a reduction in inappropriate prescribing of trimethoprim which is reported to have a significantly higher rate of non-susceptibility in ‘at risk’ groups; these are defined in PHE Management of Infection Guidelines: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/524986/2016ManagingCommonInfectionsSummaryTable.pdf

Prescribing data also demonstrates the variation in prescribing practice across CCGs and further supports the view that this is an area that requires and is amendable to improvement.

**Part C) sustained reduction of inappropriate prescribing in primary care.**

This QP also aims to sustain improvements enabled by the previous QP which successfully delivered a reduction in the prescribing of antibiotics (by 7.3%, 2.6 million prescriptions), including board spectrum antibiotics (which reduced from 3.9m prescriptions in 2014-15 to 3.3m the following year) within primary care. CCGs will be expected to ensure items per STAR-PU are equal to or below England 2013/14 mean performance value of 1.161 items per STAR-PU, and in 2018/19 CCGs will be expected to continue to reduce antibacterial items per STAR-PU to or below a new England target of 0.965 items per STAR-PU to achieve full payment in this section. CCGs who reduce antibacterial items to at or below 1.161 items per STAR-PU will receive partial payment.

<table>
<thead>
<tr>
<th>Technical Definition</th>
<th>Part A) Reducing gram negative blood stream infections across the whole health economy.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>i. A reduction in all <em>E coli</em> BSI reported at CCG level, independent of the time of onset of BSI. A 10% reduction attracts 20% of the weighting. Two extra milestones of 15% and 20% reductions have been added (total 30% weighting). See partial payment table below:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reduction against baseline</th>
<th>% QP available</th>
</tr>
</thead>
<tbody>
<tr>
<td>20% +</td>
<td>30%</td>
</tr>
<tr>
<td>15 – 19.99%</td>
<td>25%</td>
</tr>
<tr>
<td>10 – 14.99%</td>
<td>20%</td>
</tr>
<tr>
<td>&lt;10%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Baseline rates have been set and published in 2016/17 using Jan-Dec 2016 performance data currently captured via the PHE DCS system and published online http://fingertips.phe.org.uk/profile/amr-local-indicators/data. Targets are published in part a)
Performance will be measured using FY 2018/19 data.

To support the health economy to achieve these reductions CCGs will need to:


Addition to the PHE DCS reporting system for E.coli BSI is not compulsory, but is desirable, and CCGs do now have DCS write authority to add individual patient data to the DCS record for all GNBSI

**Part B) reduction of inappropriate antibiotic prescribing for UTI in primary care.**

Individual practice reduction to be decided by the CCG.

i. **A 10% reduction (or greater) in the number of trimethoprim items prescribed to patients aged 70 years or greater on baseline data (June15-May16) in 2017/18, increasing to a 30% reduction (or greater) in 2018/19.**

**Numerator:** Number of prescription items for trimethoprim with identifiable NHS number and age 70 years or greater within the CCG.

**Prescribing Data:**

This information will be obtained from the electronic Prescribing Analysis and Cost tool (ePACT) provided by NHS Business Services Authority which covers prescriptions prescribed by GPs, nurses, pharmacists and others in England and dispensed in the community in the UK.

[http://www.nhsbsa.nhs.uk/PrescriptionServices/3607.aspx](http://www.nhsbsa.nhs.uk/PrescriptionServices/3607.aspx)


For data at CCG level, prescriptions written by a prescriber located in a particular CCG but dispensed outside that CCG will be included in the CCG in which the prescriber is based. Prescriptions written in England but dispensed outside England are included. Prescriptions dispensed in hospitals, dental prescribing and private prescriptions are not included in the data.

The data is to include prescribing by Out of Hours and Urgent Care services
where relevant prescribing data is captured within the CCG data set. Cost centres that support Vanguard Integrated Urgent Care Hub prescribing may be excluded from the CCG data set (this can be agreed individually with NHS Improvement).

**Part C) sustained reduction of inappropriate prescribing in primary care.**

i. **Items/ STAR-PU must be equal to or below England 2013/14 mean performance value of 1.161 items per STAR-PU.**

ii. **2018/19 additional reduction in Items/ STAR-PU must be equal to or below England 2015/16 mean performance value of 0.965 items per STAR-PU**

**Numerator:** Number of prescription items for antibacterial drugs (BNF 5.1) within the CCG.

**Denominator:** Total number of Oral antibacterials (BNF 5.1 sub-set) ITEM based Specific Therapeutic group Age-Sex Related Prescribing Unit (STAR-PUs).

[http://www.hscic.gov.uk/prescribing/measures](http://www.hscic.gov.uk/prescribing/measures)

**Prescribing Data:**

This information can be obtained from the Information Services Portal (ISP) or the electronic Prescribing Analysis and Cost tool (ePACT) provided by NHS Business Services Authority which cover prescriptions prescribed by GPs, nurses, pharmacists and others in England and dispensed in the community in the UK.

[http://www.nhsbsa.nhs.uk/PrescriptionServices/3607.aspx](http://www.nhsbsa.nhs.uk/PrescriptionServices/3607.aspx)


For data at CCG level, prescriptions written by a prescriber located in a particular CCG but dispensed outside that CCG will be included in the CCG in which the prescriber is based. Prescriptions written in England but dispensed outside England are included. Prescriptions dispensed in hospitals, dental prescribing and private prescriptions are not included in the data. The data is to include prescribing by Out of Hours and Urgent Care services where relevant prescribing data is captured within ISP. Cost centres that support Vanguard Integrated Urgent Care Hub prescribing may be excluded from the CCG data set (this can be agreed individually with NHS Improvement).

**Data Source**

**Part A) reducing gram negative blood stream infections across the whole health economy.**

For this part of the QP, data will be taken from PHE DCS system to both collect data for GNBSI and monitor progress on E coli BSI.

This will be on the Fingertips AMR Portal

### Part B) reduction of inappropriate antibiotic prescribing for UTI in primary care.

The NHSBSA ePACT2 Antimicrobial Stewardship dashboard reports prescription items with patient age data. The AMS dashboard reports CCG performance with this QP, and supports wider antimicrobial stewardship activity at CCG and GP practice level. Prescribing data for all elements of this part of the QP will be reported by NHS BSA on a monthly basis as a rolling 12 monthly value.

| Published Frequency & Timeliness | **Part A:** The number of *E. coli* BSIs are reported at a CCG level by PHE and published quarterly. Information will be available via the Fingertips AMR Portal [http://fingertips.phe.org.uk/profile/amr-local-indicators/data](http://fingertips.phe.org.uk/profile/amr-local-indicators/data)  

**Part B and C:** Prescribing data is reported monthly at a CCG level by NHSBSA Prescription Services. To support GNBSI QP performance monitoring both GNBSI QP antibiotic indicators will be reported monthly (with existing 3 month lag), as a rolling 12 monthly data set at CCG level. This will be presented in the antibiotic monitoring dashboard published on the NHS England QP web page. [https://www.england.nhs.uk/resources/resources-for-ccgs/ccg-out-tool/ccg-ois/anti-dash/](https://www.england.nhs.uk/resources/resources-for-ccgs/ccg-out-tool/ccg-ois/anti-dash/)  

This follows the existing system to support the current QP activity. In addition the new ePACT2 platform on Oracle contains an Antimicrobial Stewardship dashboard to support CCGs to deliver these elements of the QP. This dashboard will also support reporting of the CCG IAF AMR indicators. |
Appendix 2: 2017/18 Scheme

1 Background

The Quality Premium (QP) scheme is about rewarding Clinical Commissioning Groups (CCGs) for improvements in the quality of the services they commission. The scheme also incentivises CCGs to improve patient health outcomes and reduce inequalities in health outcomes and improve access to services.

As in previous years, it is important that we retain a focus on the fundamentals of everyday commissioning. These include delivery of the NHS Constitution commitments on Referral to Treatment (RTT) Times, Accident and Emergency (A&E), ambulance and cancer waiting times; adhering to quality regulatory standards and delivering financial balance. The QP scheme will view CCG performance in the planning submissions round on the national and local priorities as well as on the fundamentals of commissioning to recognised standards.

2 Value

Under the National Health Service Act 2006 (as amended by the Health and Social Care Act 2012), NHS England has the power to make payments to CCGs to reflect the quality of services that they commission, the associated health outcomes and reductions in inequalities.

In keeping with previous years, the maximum QP payment for a CCG is expressed as £5 per head of population, calculated using the same methodology as for CCG running costs, and made as a programme allocation (This is in addition to a CCG’s main financial allocation and in addition to its running costs allowance).

3 Composition of the Quality Premium Scheme

This is a two year Quality Premium scheme. The QP paid to CCGs in 2018/19 and 2019/20 reflects the quality of the health services commissioned by them in 2017/18 and 2018/19. The QP award will be based on measures that cover a combination of national and local priorities, and on delivery of the gateway tests, as described below.
3.1 National and Local Indicators
There are five national measures and in total these are worth 85% of the QP (full
details are set out in Appendix 3):

<table>
<thead>
<tr>
<th>#</th>
<th>Indicator Name</th>
<th>Weighting</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Early Cancer Diagnosis</td>
<td>17%</td>
</tr>
<tr>
<td>2</td>
<td>GP Access and Experience</td>
<td>17%</td>
</tr>
<tr>
<td>3</td>
<td>Continuing Healthcare</td>
<td>17%</td>
</tr>
<tr>
<td>4</td>
<td>Mental Health</td>
<td>17%</td>
</tr>
<tr>
<td>5</td>
<td>Bloodstream Infections</td>
<td>17%</td>
</tr>
</tbody>
</table>

CCGs can select one local indicator which will be worth 15% of the QP. The indicator
should be selected from the RightCare suite of indicators – as set out in the
Commissioning for Value packs, focussing on an area of unwarranted variation
locally which offers the potential for CCGs to drive improvement.

The level of improvement needed to trigger the reward will be agreed locally between
the CCG and NHS England regional team, ensuring that this is robust and offers a
stretching ambition.

CCGs will be required to submit their locally agreed indicator definition and level of
improvement (as agreed with the Regional Team) early in 2017 via Unify.

3.2 Quality Gateway

CCGs are responsible for the quality of the care and treatment that they commission
on behalf of their population. NHS England reserves the right not to make any quality
premium payments to a CCG in cases of serious quality failure, ie where it is
identified that:

- a local provider has been subject to enforcement action by the Care Quality
  Commission; or
- a local provider has been flagged as a quality compliance risk and/or have
  requirements in place around breaches of provider licence conditions; or
- a local provider has been subject to enforcement action based on a quality risk;
  and
- it has been identified through NHS England’s assessment of the CCG, in respect
  of the quality and governance elements of the Improvement and Assessment
  Framework, that the CCG is not considered to be making an appropriate,
  proportionate response with its partners to resolve the above quality failure; and
- this continues to be the position for the CCG at the end of year assessment.

As an alternative to withholding the Quality Premium in the circumstances above,
NHS England may, at its discretion, make the Quality Premium available to the
relevant CCG if the CCG agrees to use the quality premium payment to help resolve
the serious quality failure.
It is important that the Quality Premium and assessment processes are well aligned. Should the assessment process criteria with respect to quality failure change during the two-year period, NHS England may amend the above criteria in order to maintain alignment with it, including if assessment criteria are introduced to identify quality failures within CCGs.

3.3 Financial Gateway

Effective use of public resources should be seen as an integral part of securing high-quality services. A CCG will not receive a quality premium if:

- in the view of NHS England, during the relevant financial year the CCG has not operated in a manner that is consistent with the obligations and principles set out in Managing Public Money\(^7\); or
- the CCG ends the relevant financial year with an adverse variance against the planned surplus, breakeven or deficit financial position\(^8\), or requires unplanned financial support to avoid being in this position; or
- it receives a qualified audit report in respect of the relevant financial year.

---


\(^8\) CCGs are measured against all delegated budgets
3.4 NHS Constitution Gateway

As in previous years, a CCG may have its Quality Premium award reduced via the NHS Constitution gateway. In 2017/18, some providers will continue to have agreed bespoke trajectories, as part of the operation of the Sustainability and Transformation Fund, for delivery of RTT, four hour A&E, 62 day cancer waits and Red 1 ambulance response times. On this basis, the CCG gateway test in respect of these measures will be adjusted to reflect these different requirements.

<table>
<thead>
<tr>
<th>NHS Constitution Requirement</th>
<th>Reduction to Quality Premium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum 18 weeks from referral to treatment - incomplete standard</td>
<td>25%</td>
</tr>
<tr>
<td>Maximum four hour waits in A&amp;E departments standard</td>
<td>25%</td>
</tr>
<tr>
<td>Maximum two month (62-day) wait from urgent GP referral to first definitive treatment for cancer</td>
<td>25%</td>
</tr>
<tr>
<td>Maximum 8 minute response for Category A (Red 1) ambulance calls</td>
<td>25%</td>
</tr>
</tbody>
</table>

In keeping with the need to keep the Quality Premium and CCG assessment processes well aligned, it is important to ensure alignment between the payment of the Quality Premium and the NHS Constitution Gateway. Should the measures in the NHS Constitution be updated, as occurred with RTT, or expectations around the operation of the Sustainability and Transformation Fund change, NHS England may amend the above criteria in order to maintain alignment.

4 Calculation and use of Quality Premium payments

The maximum QP payment for a CCG will be expressed as £5 per head of population, calculated using the same methodology as for CCG running costs (This is in addition to a CCG’s main financial allocation and in addition to its running costs allowance).

For each measure where the identified quality threshold is achieved, the CCG will be eligible for the indicated percentage of the overall funding available to it. Where a CCG has failed to meet the requirements of the quality or financial gateways set out above, it will not receive a QP payment except where NHS England exercises its discretion with respect to the quality gateway.

Where a CCG does not deliver the identified patient rights and pledges on waiting times, or any bespoke trajectories towards these (in the case of CCGs who commission from providers in receipt of the Sustainability and Transformation Fund (STF)), a reduction for each relevant NHS Constitution measure will be made to the QP payment.

It is planned that CCGs will be advised of the level of their QP award in quarter 3 of the following financial year (with the exception of the Cancers diagnosed at early stage measure – please refer to Appendix 3 below). In order to maximise its ability to
make the most effective use of the payment within 2018/19 and 2019/20, each CCG should consider making plans for use of the payment in advance of this date, so that these plans can be implemented as soon as the level of award is confirmed.

QP payments can only be used for the purposes set out in regulations\(^9\). These state that QP payments should be used by CCGs to secure improvement in:

- the quality of health services; or
- the outcomes achieved from the provision of health services; or
- reducing inequalities between patients, in terms of their ability to access health services or the outcomes achieved.

CCGs may utilise the QP payment with other organisations to deliver the improvements above where appropriate wider powers are available for the use of the funding in this manner.

Each CCG is required\(^{10}\) to publish an explanation of how it has spent a QP payment.

---

\(^9\) The National Health Service (Clinical Commissioning Groups-Payments in Respect of Quality) Regulations 2013 (S.I. 2013/474)

\(^{10}\) Section 223K(7) of the NHS Act 2006
Appendix 3: Quality Premium measures (2017/18 Scheme)

<table>
<thead>
<tr>
<th>Quality Premium Measure</th>
<th>Cancers diagnosed at early stage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Threshold</strong></td>
<td>To earn this portion of the Quality Premium, CCGs will need to either:</td>
</tr>
<tr>
<td></td>
<td>3. Demonstrate a 4 percentage point improvement in the proportion of cancers (specific cancer sites, morphologies and behaviour*) that are diagnosed at stages 1 and 2 in the 2017 calendar year compared to the 2016 calendar year. For year 2 (2018/19) this will be the 2018 calendar year compared to the 2017 calendar year.</td>
</tr>
<tr>
<td></td>
<td>Or</td>
</tr>
<tr>
<td></td>
<td>4. Achieve greater than 60% of all cancers (specific cancer sites, morphologies and behaviour*) that are diagnosed at stages 1 and 2 in the 2017 calendar year. For year 2 (2018/19) this will be the 2018 calendar year.</td>
</tr>
<tr>
<td><strong>Value</strong></td>
<td>17% of Quality Premium</td>
</tr>
<tr>
<td><strong>Rationale</strong></td>
<td>Cancer survival rates in England have never been higher, but we know that we often lag behind the highest performing countries in the world in international comparisons. We also know that the earlier cancer is diagnosed, the more likely it is to be successfully treated, and survival rates can be dramatically improved. The independent cancer taskforce, in their report Achieving World-Class Cancer Outcomes, published in July 2015, set an ambition for the NHS that 62% of all cancers with known stage at diagnosis would be diagnosed at stages 1 and 2 by 2020. Achieving this target will require every CCG to focus on and make significant improvement in early stage diagnoses.</td>
</tr>
<tr>
<td></td>
<td>Specific public health interventions, such as screening programmes and public information campaigns can aim to improve rates of early diagnosis. Supporting clinicians to spot cancers earlier and greater GP access to diagnostic and specialist advice were outlined in the Five Year Forward View as key planks of improving our diagnostic strategies. In addition, NICE published new guidance on appropriate referral for suspected cancer in 2015, which lowered the threshold of risk for symptoms suggestive of cancer to trigger an urgent referral for suspected cancer to 3%, with the aim of diagnosing more cancers at an early stage.</td>
</tr>
<tr>
<td></td>
<td>An indicator on the proportion of cancers diagnosed at an early stage is therefore a useful measure for assessing improvement in early diagnosis and ultimately cancer survival. Improving cancer survival is one of the three key ambitions outline in Achieving World-</td>
</tr>
</tbody>
</table>
**Class Cancer Outcomes.**

Thresholds have been set based on levels of improvement previously seen amongst high-performing CCGs and felt to be achievable for the majority of CCGs.

| Technical Definition | New cases of cancer diagnosed at stage 1 and 2 as a proportion of new cases of cancer diagnosed (specific cancer sites, morphologies and behaviour*).  
Numerator: Cases of cancer diagnosed at stage 1 or 2, for the specific cancer sites, morphologies and behaviour*.  
Denominator: All new cases of cancer diagnosed at any stage or unknown stage, for the specific cancer sites, morphologies and behaviour*.  
*invasive malignancies of breast, prostate, colorectal, lung, bladder, kidney, ovary, uterus, non-Hodgkin lymphomas, and invasive melanomas of skin. |
|---|---|
The most recent data is available at: [http://www.ncin.org.uk/publications/survival_by_stage](http://www.ncin.org.uk/publications/survival_by_stage)  
The quarterly data referenced is available here: [http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/cancer_outcome_metrics](http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/cancer_outcome_metrics) |
| Published Frequency & Timeliness | Data will be a rolling window of one year's worth of data. The data will be lagged by 12 months.  
Due to the fact that the data is lagged by 12 months, payment of the Quality Premium award will be made in two stages. Details of this will be provided in the Assessment Methodology which will be circulated to CCGs following the QP performance year. |
<table>
<thead>
<tr>
<th>Quality Premium Measure</th>
<th>Overall experience of making a GP appointment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Threshold</td>
<td>To earn this portion of the Quality Premium, CCGs will need to demonstrate in the July 2018 publication, either:</td>
</tr>
</tbody>
</table>
|                         | • Achieve a level of 85% of respondents who said they had a good experience of making an appointment, or;  
|                         | • A 3 percentage point increase from July 2017 publication on the percentage of respondents who said they had a good experience of making an appointment. |
| Value                   | 17% of Quality Premium |
| Rationale               | The GP Patient Survey (GPPS) seeks the views of 2.4 million people every year about their experience of GP services and results are published at GP practice level. |
|                         | The survey gives patients the opportunity to provide feedback on a number of aspects of their experience of their GP practice, and provides a rich source of quantitative data on patients’ experiences of the access and quality of care they receive.  
|                         | Access to GP services and, in particular, the ease of making an appointment is a key measure of patient experience and affects the wider healthcare system as patients who find it difficult to access GP services may seek care through emergency services inappropriately. Q18 (“Overall, how would you describe your experience of making an appointment?”) of the GP Patient Survey (GPPS) is the “litmus test” indicator in this regard.  
|                         | Attaching a Quality Premium payment will also ensure that the profile and importance of insight about patient experience is underlined and it will incentivise the wider system to review and learn from the findings of the GPPS. |
**Technical Definition**

Question 18: Overall, how would you describe your experience of making an appointment?

- Very good
- Fairly good
- Neither good nor poor
- Fairly poor
- Very poor

**Numerator:** the weighted number of people answering ‘very good’ or ‘fairly good’ to question 18 of the GP Patient Survey.

This is expressed as \( \Sigma_k (wt_{new_k}) \) where \( k = 1, \ldots, p \) which are all respondents who answer question 18 with either answering ‘very good’ or ‘fairly good’.

**Denominator:** the total weighted number of people who answer question 18 of the GP Patient Survey.

This is expressed as \( \Sigma_j (wt_{new_j}) \) where \( j = 1, \ldots, q \) which are all respondents who answer question 18.

**Weighting:**

A weight is applied to construct the indicator. The GP Patient Survey includes a weight for non-response bias \( (wt_{new}) \). This adjusts the data to account for potential differences between the demographic profile of all eligible patients in a practice and the patients who actually complete the questionnaire. The non-response weighting scheme has been developed by Ipsos MORI, incorporating elements such as age and gender of the survey respondent as well as factors from the area where the respondent lives such as level of deprivation, ethnicity profile, ACORN classification and so on, which have been shown to impact on non-response bias within the GP Patient Survey. Further information on the current weighting scheme can be found in the survey’s technical annex:


**Data Source**

Data for this indicator is from the GP Patient Survey. This survey is commissioned by NHS England and is conducted by the independent survey organisation Ipsos MORI.

**Published Frequency & Timeliness**

This has been published in July representing data collection from January to March.
<table>
<thead>
<tr>
<th>Quality Premium Measure</th>
<th>NHS Continuing Healthcare (NHS CHC)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Threshold</strong></td>
<td>This is a two part indicator, each part of which attracts 50% of the payment for the indicator:</td>
</tr>
</tbody>
</table>
|                         | Part a) worth 50%  
To achieve the Quality Premium for this part, CCGs must ensure that in more than 80% of cases with a positive NHS CHC Checklist, the NHS CHC eligibility decision is made by the CCG within 28 days from receipt of the Checklist (or other notification of potential eligibility). |
|                         | Part b) worth 50%  
To achieve the Quality Premium for this part, CCGs must ensure that less than 15% of all full NHS CHC assessments take place in an acute hospital setting. |
|                         | The CHC indicator is weighted equally between Part a) and Part b), both parts attracting 50% of the indicator value. |
|                         | If a CCG achieves only Part a) or Part b), the CCG will only receive 50% of the value of the CHC indicator (that is, 8.5% of the whole Quality Premium value available). |
| **Value**               | 17% of Quality Premium |
**Rationale**

Part a) The time that elapses between the Positive Checklist (or, where no Checklist is used, other notification of the need for a full assessment) being notified to the CCG and the funding decision being made should, in most cases, not exceed 28 days.

CCGs should make all reasonable efforts to ensure the required information or participation is made available within 28 days. This should include developing protocols with services likely to be regularly involved in NHS Continuing Healthcare eligibility processes that reflect the need for information or participation within 28 days. Where the CCG commissions the service from which information or participation is regularly required, it may be appropriate to consider placing such expectations within the specification for the relevant service.

Part b) It is preferable for eligibility for NHS Continuing Healthcare to be considered after discharge from hospital when the person’s long-term needs are clearer, and for NHS-funded services to be provided in the interim. This might include therapy and/or rehabilitation, if that could make a difference to the potential further recovery of the individual in the following few months. It might also include intermediate care or an interim package of support in an individual’s own home or in a care home.

It should always be borne in mind that assessment of eligibility that takes place in an acute hospital may not always reflect an individual’s capacity to maximise their potential. This could be because, with appropriate support, that individual has the potential to recover further in the near future. It could also be because it is difficult to make an accurate assessment of an individual’s needs while they are in an acute services environment. Anyone who carries out an assessment of eligibility for NHS Continuing Healthcare should always consider whether there is further potential for rehabilitation and for independence to be regained, and how the outcome of any treatment or medication may affect ongoing needs.

In order to address this issue and ensure that unnecessary stays on acute wards are avoided, there should be consideration of whether the provision of further NHS-funded services is appropriate. This might include therapy and/or rehabilitation, if that could make a difference to the potential of the individual in the following few months. It might also include intermediate care or an interim package of support in an individual’s own home or in a care home. In such situations, assessment of eligibility for NHS Continuing Healthcare should usually be deferred until an accurate assessment of future needs can be made. The interim services (or appropriate alternative interim services if needs change) should continue in place until the determination of eligibility for NHS Continuing Healthcare has taken place. There must be no gap in the provision of appropriate support to meet the individual’s needs.
| Technical Definition | Part a) In 80% of cases with a positive NHS CHC Checklist, the NHS CHC eligibility decision is made by the CCG within 28 days from notification of the Checklist (or other notification of the need for a full assessment).

This applies to new referrals and not reviews of existing NHS CHC cases or Previously Unassessed Periods of Care cases.

**Elapsed time calculation:**
Clock starts: 28 days referral time starts from the date the CCG is notified that full consideration for NHS CHC is required i.e. a positive checklist or other notification of potential eligibility.

Clock stops: At the date the CCG makes a decision on eligibility.

**Numerator:** Number of NHS CHC eligibility decisions where the CCG makes a decision within 28 days of being notified of the need for full consideration for NHS CHC i.e. a positive checklist or other notification of potential eligibility (nb will always be a subset of the denominator figure).

**Denominator:** Total number of NHS CHC eligibility decisions made within the financial year (sum of quarterly data).

This will then provide a percentage of NHS CHC referrals that have been completed within 28 days.

The collection method uses both in-built data validations at point of entry and data quality checking post collection. The data collection is accompanied by guidance and definitions.

Part b)

**Numerator:** Number of full comprehensive NHS CHC assessments completed whilst the individual was in an acute hospital in the relevant financial year (sum of quarterly data).

**Denominator:** Total number of full NHS CHC assessments completed in the financial year (sum of quarterly data). This will then provide a percentage of full NHS CHC assessments that were completed in an acute hospital in the relevant financial year (sum of quarterly data).

The collection method uses both in-built data validations at point of entry and data quality checking post collection. The data collection is accompanied by guidance and definitions.
<table>
<thead>
<tr>
<th><strong>Data Source</strong></th>
<th>NHS England NHS CHC report (the collection is presently covered by Burden Advice and Assessment Service (BAAS) approval until 30th June 2018).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Published Frequency &amp; Timeliness</strong></td>
<td>Quarterly data collection has commenced in Q1 17/18 Q1 data will be available on 14th September 2017 (11 weeks after quarter end). For Q2 data onwards data release is planned to be brought forward a month earlier (e.g. Q2 data will be available on 9th November around 6 weeks after quarter end).</td>
</tr>
<tr>
<td>Quality Premium Measure</td>
<td>Mental Health</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Threshold</td>
<td>This Quality Premium measure consists of three indicators from which one will be chosen based upon the inequality most pertinent to a given CCG.</td>
</tr>
<tr>
<td>d) Out of area placements (OAPs).</td>
<td></td>
</tr>
<tr>
<td>e) Equity of Access and outcomes in Improving Access to Psychological Therapies (IAPT) services.</td>
<td></td>
</tr>
<tr>
<td>f) Improve inequitable rates of access to Children &amp; Young People’s Mental Health Services.</td>
<td></td>
</tr>
<tr>
<td>The CCG and NHSE Regional Team will agree the indicator most pertinent to the CCG.</td>
<td></td>
</tr>
<tr>
<td>Only one element will be applied to a given CCG and so each element will be worth 100% of the Quality Premium payment available for this indicator.</td>
<td></td>
</tr>
<tr>
<td>Each element of the Quality Premium has specific thresholds as follows:</td>
<td></td>
</tr>
<tr>
<td><strong>Part a) OAPs:</strong> a reduction in the number of inappropriate adult OAPs for non-specialist adult acute care.</td>
<td></td>
</tr>
<tr>
<td>Total number of bed days relating to out of area placements to have reduced by 33% of the baseline number as at 1 April 2017.</td>
<td></td>
</tr>
<tr>
<td><em>nb – during 2017/18 this measure refers to adult acute, older adult acute, and Psychiatric Intensive Care Unit (PICU) beds only. In future years there is likely to be an expectation to reduce OAPs for all CCG-commissioned beds (e.g. Rehabilitation). A national definition of OAPs is included in guidance.</em></td>
<td></td>
</tr>
<tr>
<td><strong>Part b) Equity of Access and outcomes in IAPT services</strong></td>
<td></td>
</tr>
<tr>
<td>1. Recovery rate of people accessing IAPT services identified as Black, Asian and minority ethnic (BAME); improvement of at least 5 percentage points each year or to same level as white British, whichever is smaller.</td>
<td></td>
</tr>
<tr>
<td>And</td>
<td></td>
</tr>
<tr>
<td>2. Proportion of people accessing IAPT services aged 65+; to increase to at least 50% of the proportion of adults aged 65+ in the local population or by at least 33%, whichever is greater in 2017/18. For 2018/19, to increase to at least 70% of the proportion of adults aged 65+ in the local population, or by an additional 33%, whichever is greater.</td>
<td></td>
</tr>
</tbody>
</table>
It is required that both elements must be met in order to meet this indicator.

**Part c) Improved Access to Children & Young People’s Mental Health Services**

The required performance in 2017/18 is whichever is the greater of:

3. at least a 14% increase in the number of individual children and young people aged under 18 with a diagnosable Mental Health condition receiving treatment by NHS funded community services when they need it in 2017/18 based on 2016/17 baseline.

4. the increase in activity necessary to enable 32% of children and young people aged under 18 with a diagnosable Mental Health condition to receive treatment in NHS funded community services when they need it in 2017/18.

Similar tests will apply in 2018/19.

**Value**

17% of the Quality Premium

CCG’s and their NHSE Regional Teams will agree the indicator to be applied to that CCG, based upon the inequality most pertinent to that CCG.

**Rationale**

*The Five Year Forward View for Mental Health* placed a particular focus on tackling inequalities. Addressing this, a mandatory Mental Health element of the Quality Premium will focus on a number of key inequalities, allowing for the targeting of particular needs pertinent to local health economies and enabling CCGs to draw together resources in order to address local priorities.

The Quality Premium will provide significant incentive for CCGs and their local partners to collaborate in pursuit of improvements in the quality of mental health outcomes.

Based on NHS England’s interpretation of a CCG’s most pertinent needs in this area, this element of QP will be addressed against one of the following inequalities:

**d) OAPs**

People requiring acute mental health care should always receive evidence based treatment, close to home and in the least restrictive setting. Unfortunately we know that too many acutely unwell people, who require inpatient care, are sent far away from their friends and families at this time when they are particularly vulnerable.

Evidence shows that people receiving care out of area have far worse outcomes than those receiving care locally and have a far higher
incidence of suicide. Furthermore, OAPs are far more costly to provide which means that public funding is not being used to best effect. This is, of course, unacceptable, and Implementing the Five Year Forward View for Mental Health agreed to the Mental Health Taskforce recommendation that inappropriate OAPs for non-specialist acute mental health care should be eliminated.

Some areas have already achieved this ambition, but there are still high levels of variation across the country. This is why OAPs are being included as a measure in the Quality Premium.

e) Equity of Access and outcomes in IAPT services

Improving access is a priority in the Five Year Forward View for Mental Health: by 2020/21 at least 25% of people with common MH conditions should access services each year. In parallel, quality should be maintained and developed; including meeting existing waiting times and recovery standards, and improving access and outcomes for all adults.

We know that people from Black, Asian and Minority Ethnic (BAME) communities can experience poorer outcomes from services than people who identify themselves as White British. In the most recently available national data (Quarter 4 2015/16) the recovery rates for people from Black Asian and Minority groups were as much as 13.6 percentage points lower than the rate for people identified as White British.

In addition, older people are under-represented in services, not accessing them as readily as people who are under 65 years of age. The percentage of over 65s completing a course of treatment is around 7% nationally, which is lower than the equivalent proportion of the adult population at approximately 13%.

Service providers and commissioners should be taking action to ensure equity of access to and outcomes from IAPT services to people irrespective of any protected characteristics (as defined under the Equalities Act 2010) in line with their Public Sector Equalities Duties (PSED). They must also pay due regard to the need to reduce health inequalities between patients in access to and outcomes from IAPT services.

There are examples of good practice in making IAPT services serve their whole population equally, and improving access for older people and outcomes for people from Black and Minority Ethnic groups is a good step towards this goal.

f) Improved rates of access to Children & Young People’s Mental Health services

Children and young people are a priority group for mental health promotion and prevention, and the Five Year Forward View for Mental
Health calls for the Future in Mind recommendations to be implemented in full. Early intervention and quick access to good quality care is vital – especially for children and young people. Waiting times should be substantially reduced, significant inequalities in access should be addressed and support should be offered while people are waiting for care.

One in ten children has a diagnosable MH disorder. This can range from short spells of depression or anxiety through to severe and persistent conditions that can isolate, disrupt and frighten those who experience them. Mental Health problems in young people can result in lower educational attainment (for example, children with conduct disorder are twice as likely as other children to leave school with no qualifications) and are strongly associated with behaviours that pose a risk to their health, such as smoking, drug and alcohol abuse and risky sexual behaviour.

Despite recognition that early intervention can be highly cost effective, a significant treatment gap persists. The last UK epidemiological study suggested that, at that time, less than 25% – 35% of those with a diagnosable Mental Health condition accessed support. Compounding this, data from the NHS benchmarking network and recent audits year on year reveal increases in referrals and waiting times, with providers reporting increased complexity and severity of presenting problems. This indicator seeks to address this inequitable treatment gap by improving access.

Addressing the difficulties in accessing the help they need NHSE has committed to helping at least 70,000 more children and young people each year to access high-quality, evidence based Mental Health care when they need it by 2020/21.

An increase of 14% accessing treatment is consistent with the national real terms improvement required to move 12 months ahead of the national trajectory, set out in Implementing the Five Year Forward View for Mental Health.

**Technical Definition**

d) OAPs – a 33% or greater reduction in OAPs is required to receive the QP.

**Numerator:** Total number of bed days people sent inappropriately out of area as at year end 31 March 2018.

**Denominator:** Total number of bed days people sent inappropriately out of area as at baseline defined by CCGs at year end.

**Source:** Clinical Audit Platform (CAP) collection on OAPs, available since December 2016

[http://content.digital.nhs.uk/oaps](http://content.digital.nhs.uk/oaps)
e) **Equity of Access and outcomes in IAPT services**
Satisfactory performance against both components required to receive the QP.

There are two components of the IAPT indicator, which is applicable in both 2017/18 and 2018/19, enabling both short and medium term improvement activity:

f) **BAME Recovery**: Recovery rate of people accessing IAPT services identified as BAME; improvement of at least 5 percentage points or to same level as white British, whichever is smaller.

   **Numerator**: Number of people from BAME groups reaching recovery.

   **Denominator**: Number of people from BAME groups completing treatment.

   **Source**: IAPT MDS, aggregated information necessary for this calculation, available quarterly since December 2016.

g) **Older People’s Access**: For 2017/18 the proportion of people accessing IAPT services aged 65+ to increase to at least 50% of the proportion of adults aged 65+ in the local population, or by at least 33%, whichever is greater.

   For 2018/19 the proportion of people accessing IAPT services aged 65+ to increase to at least 70% of the proportion of adults aged 65+ in the local population, or by an additional 33% (vs 2017/18), whichever is greater.

   **Numerator**: number of people entering treatment to IAPT Services aged 65+ as a proportion of total number of people aged 18+ entering treatment to IAPT Services.

   **Denominator**: Number of people aged 65+ in the local population as a proportion of total number of people aged 18+ in the local population.

   **Source**: IAPT MDS, aggregated information necessary for this calculation, available quarterly since December 2016. ONS population data.

Compliance is defined as achieving both components.

h) **CYP- MH Access** – in order to achieve the QP, the required performance in 2017/18 is whichever is the greater of:

   At least a 14% increase in the number of individual children and young people aged under 18 with a diagnosable Mental Health
condition receiving treatment by NHS funded community services when they need it in 2017/18 based on 2016/17 baseline.

**Numerator**: The number of children and young people aged under 18 with a diagnosable MH condition receiving treatment in NHS funded community services in the reporting period.

**Denominator**: Baseline figure for total number of individual children and young people under 18 with a diagnosable MH condition receiving treatment in NHS funded community services.

**Source:**

**Numerator**: Due to the experimental nature of these indicators the underlying data will initially be published as part of NHS Digital’s Supplementary Information pages [http://content.digital.nhs.uk/suppinfofiles](http://content.digital.nhs.uk/suppinfofiles)

**Denominator**: The baseline figure is taken from indicator 2a as signed off as part of the 2017-2019 operational and contracting planning round. Please see Annex E [https://www.england.nhs.uk/ourwork/futurenhs/deliver-forward-view/](https://www.england.nhs.uk/ourwork/futurenhs/deliver-forward-view/)

**OR:**

The increase in activity necessary to enable 32% of children and young people aged under 18 with a diagnosable MH condition to receive treatment in NHS funded community services when they need it in 2017/18.

**Numerator**: The number of children and young people aged under 18 with a diagnosable MH condition receiving treatment in NHS funded community services in the reporting period.

**Denominator**: Total number of individual children and young people under 18 with a diagnosable MH condition ie the estimated prevalence of mental ill health in the population.

**Source:**

**Numerator**: Due to the experimental nature of these indicators the underlying data will initially be published as part of NHS Digital’s Supplementary Information pages [http://content.digital.nhs.uk/suppinfofiles](http://content.digital.nhs.uk/suppinfofiles)

**Denominator**: This estimated prevalence value is taken from indicator 2b as signed off as part of the 2017-2019 operational and contracting planning round. Please see Annex E.
<table>
<thead>
<tr>
<th>Similar tests will apply in 2018/19</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://www.england.nhs.uk/ourwork/futurenhs/deliver-forward-view">https://www.england.nhs.uk/ourwork/futurenhs/deliver-forward-view</a></td>
</tr>
</tbody>
</table>
Reducing Gram Negative Bloodstream Infections (GNBSIs) and inappropriate antibiotic prescribing in at risk groups

This Quality Premium measure consists of three parts:

Part a) reducing gram negative blood stream infections (BSI) across the whole health economy.

Part b) reduction of inappropriate antibiotic prescribing for urinary tract infections (UTI) in primary care.

Part c) sustained reduction of inappropriate prescribing in primary care.

The weighting for the three measures is as follows:

Part A = 45% Part B= 45% Part C= 10%:

Part A i) will be worth 35%. Part A ii) will be worth 10%;
Part B i) will be worth 22.5% and part B ii) will be worth 22.5%;
Part C will be worth 10%.

Payment must be considered individually for each component of the QP as each part supports improvement within different areas which, individually and collectively support the overarching ambition.

This proposal outlines the details for the QP during 2017/18 however the main components of the QP should be maintained during 2018/19 to support a 2 year QP scheme. As outlined below, targets associated with each element will be reviewed so that more specific and ambitious targets can be set for 2018/19.

Part a) reduction in the number of gram negative blood stream infections across the whole health economy. The required performance in 2017/18 must be:

i. A 10% reduction (or greater) in all *E coli* BSI reported at CCG level based on 2016 performance data. 2018/19 reduction thresholds will be reviewed against the latest activity to ensure the QP supports the maximum appropriate reduction gains.

ii. Collection and reporting of a core primary care data set for all *E coli* BSI in Q2-4 2017/18. This will require completion of requisite data through the existing Public Health England Data Capture Set (PHE DCS) reporting system for *E coli* BSI and the refined data collection for primary care related aspects. Further details will be available in following publications. Collection and reporting of a core primary care data set for all *E coli* BSI will continue during 2018/19.
Part b) reduction of inappropriate antibiotic prescribing for UTI in primary care. The required performance in 2017/18 must be:

i. A 10% reduction (or greater) in the Trimethoprim: Nitrofurantoin prescribing ratio based on CCG baseline data (June15-May16) for 2017/18. In 2018/19 reduction thresholds will be reviewed to ensure targets reflect latest activity and maximise appropriate reduction gains.

ii. A 10% reduction (or greater) in the number of Trimethoprim items prescribed to patients aged 70 years or greater on baseline data (June15-May16) for 2017/18. In 2018/19 reduction thresholds will be reviewed to ensure targets reflect latest activity and maximise appropriate reduction gains.

Part c) sustained reduction of inappropriate prescribing in primary care.

i. Items per Specific Therapeutic group Age-Sex Related Prescribing Unit (STAR-PU) must be equal to or below England 2013/14 mean performance value of 1.161 items per STAR-PU. This threshold will remain during 2018/19.

<table>
<thead>
<tr>
<th>Value</th>
<th>17% of Quality Premium</th>
</tr>
</thead>
</table>
| Rationale                  | Work to develop and deliver this Quality Premium directly responds to the ambitions set by Government following the O’Neill Review on Antimicrobial Resistance (May, 2016). These ambitions include a:

- 50% reduction of Gram Negative Bloodstream Infections (GNBSIs) by 2020.
- 50% reduction of the number of inappropriate antibiotic prescriptions by 2020.

It also enables work (across the ALBs) to support the UK 5 Year AMR Strategy (2013-2018), which states that there are few public health issues of greater importance than antimicrobial resistance (AMR) in terms of impact on society. Infections are increasingly developing that cannot be treated and the rapid spread of multi-drug resistant bacteria means that we could be close to reaching a point where it is not possible to prevent or treat everyday infections or diseases.

This work will support the other clinical priority areas, across NHS England and NHS Improvement, particularly through supporting the Sepsis agenda and by informing improvements in community care. It will assist Sustainability and Transformation Planning footprints to develop and deliver Sustainability and Transformation Plans - for which patient safety, and AMR specifically, are included as key priority areas – and local AMR plans (which are being lead and supported by PHE).
Part a) reducing gram negative blood stream infections across the whole health economy

Healthcare-associated Gram-negative bacteraemias (GNB) bloodstream infections pose a significant health risk and threat to patient safety. They include infections caused by *Escherichia coli*, and *Pseudomonas aeruginosa*. Rates of bacteraemia caused by GNB vary depending on the bacterial species:

- Mandatory surveillance of *Escherichia coli* (*E.coli*) has indicated an alarming rise in rates of *E. coli* bacteraemia (60.4 to 66.2 per 100,000 population from 2012-2015).
- Rates of *Pseudomonas* spp. and *Stenotrophomonas* spp. bacteraemia have decreased steadily. (6.9 to 6.2 per 100,000 and 1.3 to 0.8 per 100,000, respectively, from 2007-2014).
- Rates of carbapenemase-producing enterobacteriaceae (CPE) are also increasing within the UK.
- Health care acquired infections (HCAIs) associated with multi-drug resistant (MDR) Gram-negative species are of utmost importance due to the difficulties in treatment associated with the limited number of effective antibiotics.

*E.coli* bacteraemia is the largest most prevalent group of GNBSI which supports the QP’s focus on these bacteraemia over the next 2 years. The reporting of *E.coli* BSI is already mandatory (via the PHE DCS system) and this provides data on which to establish a baseline and set reduction targets for 2017/18. Reduction targets should be revised for 2018/19 when (through the work done as part of the 2017/18 QP) we will understand where and how greater improvements can be supported. Reduction in other GNBSI should be considered in future years when systems should have been established to capture baseline data.

Part b) reduction of inappropriate antibiotic prescribing for Urinary Tract Infections (UTI) in primary care.

The age group with the highest rates of *E. coli* bacteraemia in England were observed amongst the elderly (75 years and over) with 402.9 and 313.5 reports per 100,000 population for males and females respectively.

The PHE enhanced data set reported to Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infections (ARHAI) 24-14 (01) for *E coli* BSI (including 3 months of data from 38 acute trusts Nov 2012-Jan 2013, reporting on 891 cases) stated that 50% of cases related to the urogenital tract and in these, 72% occurred in patients >65 years, and 64% of patients had reported at least one UTI in the previous 12 months. This supports the focus of this element of the QP.

The report states that: *is it clear that a significant proportion of the rise may be due to patients being prescribed inappropriate antibiotics, resulting in*
relapsing infections. It is important that antimicrobial prescribing is appropriate and effective. However, there remains a difficult balance between the clinical management of UTIs and the empiric prescribing of broad-spectrum antimicrobials due to increasing resistance to narrow spectrum antibiotics which limits available treatment options.

Ongoing mandatory surveillance continues to identify previous UTIs as a key risk factor. This indicator would work to increase the appropriate use of nitrofurantoin as 1st line choice for the empirical management of UTI in primary care settings, and support a reduction in inappropriate prescribing of trimethoprim which is reported to have a significantly higher rate of non-susceptibility in ‘at risk’ groups; these are defined in PHE Management of Infection Guidelines: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/524986/2016ManagingCommonInfectionsSummaryTable.pdf

Prescribing data also demonstrates the variation in prescribing practice across CCGs and further supports the view that this is an area that requires and is amendable to improvement.

**Part c) sustained reduction of inappropriate prescribing in primary care.**

This QP also aims to sustain improvements enabled by the previous QP which successfully delivered a reduction in the prescribing of antibiotics (by 7.3%, 2.6 million prescriptions), including board spectrum antibiotics (which reduced from 3.9m prescriptions in 2014-15 to 3.3m the following year) within primary care. CCGs will be expected to ensure items per STAR-PU are equal to or below England 2013/14 mean performance value of 1.161 items per STAR-PU.

<table>
<thead>
<tr>
<th>Technical Definition</th>
<th>Part a) Reducing gram negative blood stream infections across the whole health economy.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>i. <strong>A reduction target of 10% in all E coli BSI reported at CCG level - independent of the time of onset of BSI.</strong> Baseline rates will be set using 2016 performance data currently captured via the DCS system and published online <a href="http://fingertips.phe.org.uk/profile/amr-local-indicators/data">http://fingertips.phe.org.uk/profile/amr-local-indicators/data</a>.</td>
</tr>
<tr>
<td></td>
<td>iv. Collect and report a core primary care data set for all E coli BSI in Q2-4 2017/18. This will require completion of an advisory data</td>
</tr>
</tbody>
</table>

Addition to the PHE DCS reporting system for E.coli BSI is desirable but not mandatory as CCGs do not yet have DCS write authority for E.coli BSI. CCGs are expected to use Q1 2017/18 to establish a local approach to capture the core primary care data.

**Part b) reduction of inappropriate antibiotic prescribing for UTI in primary care.**

Individual practice reduction to be decided by the CCG.

ii. **A 10% reduction (or greater) in the Trimethoprim: Nitrofurantoin prescribing ratio based on CCG baseline data (June15-May16). This threshold will be reviewed for 2018/19 as highlighted above.**

**Numerator:** Number of prescription items for trimethoprim within the CCG.

**Denominator:** Number of prescription items for nitrofurantoin within the CCG.

**Prescribing Data:**

This information can be obtained from the electronic Prescribing Analysis and Cost tool (ePACT) provided by NHS Business Services Authority which covers prescriptions prescribed by GPs, nurses, pharmacists and others in England and dispensed in the community in the UK.

[http://www.nhsbsa.nhs.uk/PrescriptionServices/3607.aspx](http://www.nhsbsa.nhs.uk/PrescriptionServices/3607.aspx)


For data at CCG level, prescriptions written by a prescriber located in a particular CCG but dispensed outside that CCG will be included in the CCG in which the prescriber is based. Prescriptions written in England but dispensed outside England are included. Prescriptions dispensed in hospitals, dental prescribing and private prescriptions are not included in the data.

The data is to include prescribing by Out of Hours and Urgent Care services where relevant prescribing data is captured within the CCG data set. Cost centres that support Vanguard Integrated Urgent Care Hub prescribing may be excluded from the CCG data set (this can be agreed individually with NHS Improvement).

iii. **A 10% reduction (or greater) in the number of trimethoprim items prescribed to patients aged 70 years or greater on baseline data (June15-May16). This threshold will be reviewed for 2018/19 as highlighted above.**

**Numerator:** Number of prescription items for trimethoprim with identifiable
NHS number and age 70 years or greater within the CCG.

**Prescribing Data:**

This information will be obtained from the electronic Prescribing Analysis and Cost tool (ePACT) provided by NHS Business Services Authority which covers prescriptions prescribed by GPs, nurses, pharmacists and others in England and dispensed in the community in the UK. [http://www.nhsbsa.nhs.uk/PrescriptionServices/3607.aspx](http://www.nhsbsa.nhs.uk/PrescriptionServices/3607.aspx) [https://www.nhsbsa.nhs.uk/prescription-data/antimicrobial-stewardship](https://www.nhsbsa.nhs.uk/prescription-data/antimicrobial-stewardship)

For data at CCG level, prescriptions written by a prescriber located in a particular CCG but dispensed outside that CCG will be included in the CCG in which the prescriber is based. Prescriptions written in England but dispensed outside England are included. Prescriptions dispensed in hospitals, dental prescribing and private prescriptions are not included in the data.

The data is to include prescribing by Out of Hours and Urgent Care services where relevant prescribing data is captured within the CCG data set. Cost centres that support Vanguard Integrated Urgent Care Hub prescribing may be excluded from the CCG data set (this can be agreed individually with NHS Improvement).

**Part c) sustained reduction of inappropriate prescribing in primary care.**

iii. Items/STAR-PU must be equal to or below England 2013/14 mean performance value of 1.161 items per STAR-PU. This threshold will remain during 2018/19.

**Numerator:** Number of prescription items for antibacterial drugs (BNF 5.1) within the CCG.

**Denominator:** Total number of Oral antibacterials (BNF 5.1 sub-set) ITEM based Specific Therapeutic group Age-Sex Related Prescribing Unit (STAR-PU).

[http://www.hscic.gov.uk/prescribing/measures](http://www.hscic.gov.uk/prescribing/measures)

**Prescribing Data:**

This information can be obtained from the Information Services Portal (ISP) or the electronic Prescribing Analysis and Cost tool (ePACT) provided by NHS Business Services Authority which cover prescriptions prescribed by GPs, nurses, pharmacists and others in England and dispensed in the community in the UK. [http://www.nhsbsa.nhs.uk/PrescriptionServices/3607.aspx](http://www.nhsbsa.nhs.uk/PrescriptionServices/3607.aspx) [http://www.nhsbsa.nhs.uk/3230.aspx](http://www.nhsbsa.nhs.uk/3230.aspx)

For data at CCG level, prescriptions written by a prescriber located in a particular CCG but dispensed outside that CCG will be included in the CCG in which the prescriber is based. Prescriptions written in England but dispensed outside England are included. Prescriptions dispensed in hospitals, dental
prescribing and private prescriptions are not included in the data. The data is to include prescribing by Out of Hours and Urgent Care services where relevant prescribing data is captured within ISP. Cost centres that support Vanguard Integrated Urgent Care Hub prescribing may be excluded from the CCG data set (this can be agreed individually with NHS Improvement).

**Data Source**

<table>
<thead>
<tr>
<th>Part a) reducing gram negative blood stream infections across the whole health economy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>For this part of the QP, data will be taken from PHE DCS system to both collect data for GNBSI and monitor progress on E coli BSI.</td>
</tr>
<tr>
<td>This will be on the Fingertips AMR Portal <a href="http://fingertips.phe.org.uk/profile/amr-local-indicators/data">http://fingertips.phe.org.uk/profile/amr-local-indicators/data</a></td>
</tr>
</tbody>
</table>

**Part b) reduction of inappropriate antibiotic prescribing for UTI in primary care.**

| The NHSBSA ePACT is moving to a new platform, and this will support reporting of prescription patient age data. The AMS dashboard will be developed and this will be pre-populated with relevant information for the CCG. Prescribing data for all elements of this part of the QP will be reported by NHS BSA on a monthly basis as a rolling 12 monthly value. |

**Published Frequency & Timeliness**

<table>
<thead>
<tr>
<th>Part A: The number of E coli BSIs are reported at a CCG level by PHE and published quarterly.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Information will be available via the Fingertips AMR Portal <a href="http://fingertips.phe.org.uk/profile/amr-local-indicators/data">http://fingertips.phe.org.uk/profile/amr-local-indicators/data</a></td>
</tr>
<tr>
<td>Part B and C: Prescribing data is reported monthly at a CCG level by NHSBSA Prescription Services. To support GNBSI QP performance monitoring both GNBSI QP antibiotic indicators will be reported monthly (with existing 3 month lag), as a rolling 12 monthly data set at CCG level. This will be presented in the antibiotic monitoring dashboard published on the NHS England QP web page. <a href="https://www.england.nhs.uk/resources/resources-for-ccgs/ccq-out-tool/ccq-ois/anti-dash/">https://www.england.nhs.uk/resources/resources-for-ccgs/ccq-out-tool/ccq-ois/anti-dash/</a></td>
</tr>
<tr>
<td>This follows the existing system to support the current QP activity.</td>
</tr>
<tr>
<td>In addition the new ePACT platform on Oracle will allow the development of a dashboard to support CCGs to deliver these elements of the QP. This dashboard will also support the CCG IAF AMR indicators in the current AMR QP which will help support sustained QP activity into 2017-19.</td>
</tr>
</tbody>
</table>